Medtronic (NYSE: MDT) Posts 13.7% Revenue Growth in Q1 FY2027, Raises Full-Year Guidance

Medtronic plc (NYSE: MDT) reported first quarter fiscal 2027 results on Tuesday, September 1, delivering worldwide revenue of $9.756 billion, up 13.7% year-over-year on both a reported and organic basis, while adjusted EPS of $1.45 beat the $1.40 consensus estimate by $0.05. The company also raised its full-year fiscal 2027 guidance on both revenue growth and earnings.

Q1 FY2027 Financial Results

• Revenue: $9.756 billion, up 13.7% year-over-year from $8.578 billion, approximately 200 basis points above the guidance midpoint
• GAAP EPS: $1.14, up 40.7% from $0.81 in Q1 FY2026; adjusted EPS of $1.45, up 15.1% from $1.26
• GAAP operating income: $1.764 billion, up 22.1% year-over-year; GAAP operating margin of 18.1%, up 120 basis points
• Adjusted operating income: $2.316 billion, up 14.9%; adjusted operating margin of 23.7%, up 10 basis points
• GAAP net income: $1.470 billion, up 41.4% from $1.039 billion in the prior-year quarter

What Drove the Results

Adjusted EPS of $1.45 beat the $1.40 consensus by 3.4%. Revenue of $9.756 billion reflected broad portfolio performance, though the company estimates that an extra fiscal week in Q1 FY2027 benefited organic revenue growth by approximately $570 million.

The Cardiovascular portfolio was the largest contributor, generating $3.927 billion in revenue, up 18.9% organically. Within that segment, Electrophysiology Therapies grew 29.1% organically to $2.218 billion, while Cardiac Ablation Solutions specifically posted 88% growth. The Neuroscience portfolio contributed $2.678 billion, up 9.3% organically, with Cranial and Spinal Technologies growing 12.9% organically and Pelvic Health up 15%. The Medical Surgical portfolio added $2.279 billion, up 10.2% organically, paced by 14.2% organic growth in Acute Care and Monitoring. The Diabetes business delivered $843 million, up 14.9% organically.

GAAP net income of $1.470 billion diverged materially from adjusted net income of $1.860 billion, a gap of $390 million attributable to non-GAAP adjustments the company details in its financial schedules. GAAP GAAP EPS of $1.14 compares to adjusted EPS of $1.45 for the same period.

During the quarter, Medtronic also completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc., announced a strategic investment in Pi-Cardia for leaflet modification technology, received FDA clearance for the Touch Surgery Aide next-generation computing platform, obtained an expanded CE Mark for the Affera Mapping and Ablation System, and announced a strategic partnership with Cornerstone Robotics to expand access to robotic-assisted surgery globally.

Raised Full-Year Guidance

Medtronic raised its FY2027 organic revenue growth guidance to 7.25% to 7.75%, up from the prior range of 6.75% to 7.25%. The company also raised its full-year adjusted diluted EPS guidance to $5.94 to $6.00, compared to the prior range of $5.90 to $6.00. The guidance reflects an estimated neutral to 1% accretive impact from foreign currency exchange based on recent rates.

CFO Thierry Piéton stated that the combination of operating performance and financial discipline drove revenue and adjusted EPS ahead of expectations, enabling the guidance increase.

Wall Street View

BTIG Research issued a positive outlook for Medtronic following the results. Analyst consensus as of August 1, 2026 stood at 10 strong buy, 12 buy, and 12 hold recommendations, with no sell or strong sell ratings, a shift from July 1 when hold ratings numbered 14.

Investor Takeaway

Medtronic's Q1 FY2027 results reflect broad-based portfolio execution across all four business segments, with the Cardiovascular division's Electrophysiology Therapies line emerging as the clearest growth engine at 29.1% organic expansion. The guidance raise on both organic revenue and adjusted EPS, combined with the acceleration of new product clearances and strategic acquisitions, points to management's confidence in sustaining the growth trajectory beyond the extra fiscal week benefit. Investors will likely watch closely in subsequent quarters whether the Cardiovascular and Diabetes segments can maintain momentum without the one-week calendar tailwind. MDT shares gained 1.53% on Tuesday, September 1, while the S&P 500 declined 0.69%.